Drugs in Development
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Pegadricase
Therapeutic Area: Musculoskeletal Product Name: SEL-212
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Selecta Biosciences
Deal Size: $4.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement November 23, 2020
Details:
Selecta Biosciences, 3SBio partner, has commenced the phase III clinical program of a combination therapy involving SEL-212 for the treatment of chronic refractory gout on behalf of SobiTM, and has made a milestone payment of USD 4 million to 3SBio.
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
